Canid secures new funding for its comprehensive vaccine management solution in order to expand its geographic footprint in the U.S. and empower pediatric practices to deliver best-in-class care.
NEW YORK, Sept. 21, 2023 /PRNewswire-PRWeb/ -- Canid, the end-to-end platform for vaccine automation and management, announced today that it has closed $1.5 million in new funding to expand its geographic footprint to 10 new states across the U.S. and add new tools to manage vaccine patient populations. This round was led by SeedtoB Capital, an early-stage fund focused on healthcare innovation and artificial intelligence, with participation from FJ Labs, Alumni Ventures, I2BF and MKT1.
Canid's workflow automation solution tackles the complexity of vaccine operations, a vital but historically low-margin service for pediatric and other medical practices. By ordering and purchasing vaccines, managing billing, and leveraging its network to negotiate stronger rates and maximize reimbursement, Canid mitigates clinical and administrative workload. Its provider-friendly solution eliminates the need for manual data entry and record-keeping, optimizes inventory in real-time, and empowers practices to run large-scale vaccine clinics. Canid's unique suite of tools offers practices a unified way to engage patients and close care gaps, while minimizing provider burnout and delivering higher-quality care.
"Vaccinations have been taken for granted for decades. They're the #1 most valuable public health tool we have as a society, and yet they're always the last priority for our healthcare system. We're at a point where doctors and patients alike see vaccines as a burden instead of the life-saving preventative care interventions that they are. Our goal at Canid is to change that. By eliminating the burden out of giving and receiving vaccines, we hope to make it exciting again to take part. This starts at the doctor's office, where a typical pediatrician's office will give vaccines to hundreds of kids per day." said Pedro Sanchez de Lozada, founder and CEO of Canid.
"Canid is currently live in 4 states, 3 of which have been added in the past quarter. We're excited to support Pedro and team to expand across the Southwest and Midwest United States to meet the demand for a new way to vaccinate" said Ritesh Sharma, Managing Partner at SeedtoB Capital. "As Canid works with larger and larger swaths of the population country-wide, new tools enabling the company to improve vaccination rates will be critical to expanding the impact of their methodology."
Based in New York, NY, Canid is an end-to-end vaccine workflow automation and management solution, allowing practices to more effectively manage the purchasing, delivery, and record management of vaccines. By eliminating the administrative complexity of vaccine delivery, Canid empowers clinicians to deliver higher-quality care and ultimately drive improvements in public health.
About SeedtoB Capital
Based in Atlanta, GA, SeedtoB Capital invests in early-stage businesses driving adoption of innovative technology within the healthcare ecosystem. The firm was founded by Ritesh Sharma and Shantanu Nigam, serial entrepreneurs who founded Jvion and quickly grew it into the nation's largest clinical AI company. SeedtoB Capital is focused on helping entrepreneurs navigate the complexities of healthcare and chart the most efficient path toward Series B – and ultimately, company success.
SOURCE SeedtoB Capital